Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 107,264 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

Postplacental LNG-IUD Ultrasound Use Study

NCT04474548
View directory record Official record
Conditions
IUD Insertion Complication
Interventions
Ultrasound use
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Female only
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Completed No phase listed Observational

Effect of Atorvastatin (Lipitor) on Gene Expression in People With Vascular Disease

NCT00293748
View directory record Official record
Conditions
Vascular Disease, Vascular Disease Risk
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 30, 2026, 11:16 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

NCT02519348
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Tremelimumab, Durvalumab, Bevacizumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
16
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Phase 2 Interventional

A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer

NCT00001426
View directory record Official record
Conditions
Ovarian Neoplasm
Interventions
Cyclophosphamide, Paclitaxel, Cisplatin, G-CSF
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 30, 2026, 11:16 PM EDT
Terminated No phase listed Observational Results available

Arrythmia Burden in Cardiac Contractility Modulation (CCM)

NCT05704426
View directory record Official record
Conditions
Atrial Fibrillation, Arrythmia
Interventions
Impulse Dynamics Optimizer Device
Device
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Phase 3 Interventional Results available

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

NCT03656926
View directory record Official record
Conditions
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions
Liposomal Cyclosporine A, Standard of Care
Drug
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Recruiting Early Phase 1 Interventional

Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

NCT07144826
View directory record Official record
Conditions
Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma, Stage II Ovarian Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8
Interventions
Biospecimen Collection, Placebo Administration, Probiotic, Questionnaire Administration
Procedure · Drug · Dietary Supplement + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Phase 2 Interventional

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

NCT01435226
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GS-5885, GS-9451, tegobuvir, placebo to match tegobuvir, placebo to match RBV, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
37
States / cities
Tucson, Arizona • Anaheim, California • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Early Phase 1 Interventional

Pilot Study of Imatinib Cetuximab Combo for H & N Cancer

NCT05816785
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
Cetuximab, Imatinib
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

SH Dr. Chen Gastric Bypass Study

NCT05357443
View directory record Official record
Conditions
Gastric Bypass
Interventions
Gastric bypass with transection of vagal nerves, Gastric bypass without transection of vagal nerves
Procedure
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Early Childhood Obesity, Part 1: Family Spirit Nurture, 3-9 Months

NCT03101943
View directory record Official record
Conditions
Obesity, Water; Lack of, Breast Feeding, Tooth Erosion, Dental Plaque, Infant Obesity, Feeding Behavior, Mother-Child Relations, Dietary Habits, Dental Caries
Interventions
Family Spirit Nurture (FSN), Control Program, Water Delivery
Behavioral · Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
13 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Shiprock, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 30, 2026, 11:16 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma

NCT01783535
View directory record Official record
Conditions
Retinoblastoma
Interventions
vincristine, topotecan, filgrastim, PEG-filgrastim, carboplatin, focal therapy, etoposide, cyclophosphamide, MESNA, doxorubicin, enucleation, external beam radiation or proton beam radiation
Drug · Other · Procedure + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of High Fat Diet on Muscle Metabolism

NCT02328235
View directory record Official record
Conditions
Diabetes
Interventions
High Saturated Fat Diet
Other
Lead sponsor
Kevin Davy
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Siplizumab in T1DM

NCT05574335
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Siplizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Aurora, Colorado • Iowa City, Iowa • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Interaction Effects of Temperature and Ozone

NCT01981135
View directory record Official record
Conditions
Exposure to Environmental Pollution, Non-occupational
Interventions
Clean Air, Ozone
Other
Lead sponsor
Environmental Protection Agency (EPA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 30, 2026, 11:16 PM EDT
Terminated Phase 3 Interventional Results available

Study of Fentanyl-Propofol-EMLA of L.M.X4 Technique for Bone Marrow Aspiration

NCT00187135
View directory record Official record
Conditions
Bone Marrow Disease, Pain
Interventions
Fentanyl, EMLA, L.M.X4, Propofol
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 17 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Phase 1 Interventional

The Role of Phosphodiesterase Inhibitors in Incretin Secretion

NCT02363335
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, Roflumilast/Sitagliptin, Sitagliptin, Roflumilast
Other
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Not applicable Interventional

Evaluating the Effectiveness of 2 Surgical Skin Preparation Methods in Reducing Surgical Wound Drainage After Total Hip or Knee Replacement

NCT01097135
View directory record Official record
Conditions
Drainage
Interventions
Duraprep Surgical Solution
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 30, 2026, 11:16 PM EDT
Recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

NCT04301076
View directory record Official record
Conditions
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide, Lenalidomide, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Vincristine Sulfate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Atlanta, Georgia • City of Saint Peters, Missouri • Creve Coeur, Missouri + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects

NCT04520217
View directory record Official record
Conditions
Photosensitivity, Microvesicle Particle
Interventions
4% Imipramine Cream, Base Cream
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Study of Setmelanotide in Hypothalamic Obesity

NCT04725240
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
San Diego, California • Gainesville, Florida • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Phase 1 Interventional

XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib

NCT00920868
View directory record Official record
Conditions
Solid Tumor, Metastatic Colorectal Cancer
Interventions
dasatinib, bevacizumab, Oxaliplatin, Capecitabine
Drug
Lead sponsor
Herbert Hurwitz, MD
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Denver, Colorado • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 30, 2026, 11:16 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cannabis Association With Sleep Study

NCT06982950
View directory record Official record
Conditions
Sleep
Interventions
Manipulation of Sleep Duration
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 29 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Phase 1Phase 2 Interventional

Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer

NCT00002950
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, topotecan hydrochloride
Biological · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 30, 2026, 11:16 PM EDT